ResearcherArmy Medical UniversityActive in the last 2 years
Xiaobing Huang
Matched on ORCID iD 0009-0001-2083-7663; OpenAlex author ID A5102917854. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 7
- Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1080/1744666x.2024.2448989↗
- Clinical efficacy and chemoresistance analysis of precision neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a prospective, single-arm pil… Co-author DOI 10.1097/js9.0000000000002342↗
- Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. Last author DOI 10.3389/fonc.2023.1167144↗
- Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/sjg.sjg_356_21↗
- Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study. First author DOI 10.4251/wjgo.v14.i9.1785↗
- Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells by blocking the activation of p65 and p… Last author DOI 10.21037/jgo-20-533↗
- COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.22520↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yichen Tang · 4 shared papers, 2021–2023 · strength 0.71
- Paper Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma. DOI 10.4103/sjg.sjg_356_21↗
- Paper Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. DOI 10.3389/fonc.2023.1167144↗
- Paper Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinom… DOI 10.4251/wjgo.v14.i9.1785↗
- Yonggang He · 3 shared papers, 2021–2025 · strength 0.58
- Paper Clinical efficacy and chemoresistance analysis of precision neoadjuvant chemotherapy for borderline resectable pancreat… DOI 10.1097/js9.0000000000002342↗
- Paper Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinom… DOI 10.4251/wjgo.v14.i9.1785↗
- Paper Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells… DOI 10.21037/jgo-20-533↗
- Yonggang He · 2 shared papers, 2023–2025 · strength 0.43
- Paper Impact of anti-PD1 immunotherapy and circulating tumor cells on progression-free survival in surgical pancreatic adenoc… DOI 10.1080/1744666x.2024.2448989↗
- Paper Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. DOI 10.3389/fonc.2023.1167144↗
- Lu Zheng · 3 shared papers, 2017–2023 · strength 0.40
- Paper Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. DOI 10.3389/fonc.2023.1167144↗
- Paper Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells… DOI 10.21037/jgo-20-533↗
- Paper COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. DOI 10.1002/mc.22520↗
- Lu Zheng · 1 shared paper, 2025 · strength 0.27
- Lu Zheng · 1 shared paper, 2025 · strength 0.26
- Nan You · 2 shared papers, 2017–2023 · strength 0.24
- Jing Li · 1 shared paper, 2022 · strength 0.22
- Lu Zheng · 1 shared paper, 2022 · strength 0.16
- Liang Wang · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.